Montana has become the first state to create a parallel approval pathway for experimental medications, effectively circumventing federal FDA oversight. As of this week, biotech companies with drugs that have completed only preliminary testing—sometimes involving as few as 10 healthy participants—can pay $12,500 to submit their therapies to Montana's newly established review board. Once approved, these drugs can be sold directly to consumers within the state. The move represents an unprecedented challenge to the FDA's regulatory monopoly and reflects growing frustration among patients and families desperate for access to treatments that have not completed standard clinical trials. The policy targets rare genetic disorders and conditions where no approved treatments exist, positioning Montana as an experimental medical hub for biotech innovation.
The legislative impetus stems partly from compelling patient narratives. Kris DeVault's two-year-old son Brody suffers from a developmental delay disorder with no FDA-approved treatment options. Facing the prospect of waiting years for conventional clinical trials and FDA approval, families like DeVault's view Montana's new pathway as a lifeline. However, medical authorities and patient safety advocates express serious concern. The FDA has not publicly commented on Montana's framework, but the accelerated approval model echoes previous regulatory shortcuts with troubling outcomes. Aducanumab, an Alzheimer's drug granted accelerated FDA approval in 2021 with limited efficacy evidence, was subsequently withdrawn from the market after studies showed it failed to slow cognitive decline, leaving patients who had paid thousands of dollars disappointed and potentially harmed.
Montana's approach fundamentally differs from the FDA's tiered approval system, which requires Phase I, II, and III clinical trials demonstrating both safety and efficacy before market authorization. The state review board operates without the infrastructure, expertise, or independent manufacturing oversight that federal regulators provide. Critics warn that Montana's $12,500 application fee creates perverse incentives, potentially attracting companies with marginal science rather than breakthrough therapies. Patient advocates remain divided: some embrace expanded access as moral necessity, while others fear vulnerable populations will become test subjects for inadequately vetted treatments. As other states consider similar legislation, Montana's experiment will likely define the regulatory boundaries between state autonomy and federal drug safety standards for years to come.